- Home
- ZTEK vs NSRX Comparison
ZTEK vs NSRX Comparison
Compare ZTEK & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | NSRX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 63.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | NSRX |
|---|---|---|
| Price | $0.79 | $5.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 98.9K | 8.5K |
| Earning Date | 02-27-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $657,134.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2225.73 | N/A |
| 52 Week Low | $0.62 | $5.90 |
| 52 Week High | $1.84 | $9.99 |
Technical Indicators
Market Signals| Indicator | ZTEK | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 38.60 |
| Support Level | $0.80 | $6.50 |
| Resistance Level | $0.89 | $7.70 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 15.42 | 0.00 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.